Application of miR-22 in preparation of bladder cancer chemosensitization treatment drugs as target site

A therapeutic drug, 1. The technology of mir-22, applied in the field of biomedicine, can solve the problems such as unclear influence of paclitaxel

CN107432933AInactive Publication Date: 2017-12-05THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
0 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2017-12-05
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

MiR-22 can realize the targeting negative regulation of the expression of REDD1, and the miR-22 is under-expressed in bladder cancer tissues. The miR-22 can influence the sensitivity of bladder cancer cells to paclitaxel chemotherapy through the "REDD1-autophagy" regulation axis, so the miR-22 can be used as a potential target for bladder cancer chemosensitization, and can be used in the preparation of the bladder cancer chemosensitization treatment drugs as the target site, and especially the miR-22 can be used for preparing drugs for inhibiting autophagy and increasing the sensitivity of bladder cancer cells to paclitaxel chemotherapy as the target site. The bladder cancer is BUC.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of miR-22 as a target site in the preparation of chemotherapy sensitization drugs for bladder cancer. Background technique

[0002] BUC is the most common malignant tumor in the urinary system with high recurrence and progression rates. Surgical resection is the standard treatment for BUC, but 50% of patients with muscle-invasive BUC die within 2 years of postoperative recurrence and metastasis. Combined chemotherapy can reduce the recurrence rate of bladder cancer and improve the survival rate of patients. The microtubule stabilizer paclitaxel has been shown to have a good effect on BUC. A recent phase III clinical trial found that the PCG regimen with the addition of paclitaxel to the standard chemotherapy regimen cisplatin plus gemcitabine (GC) can effectively improve the overall response rate and overall survival rate of BUC. However, the oc...

Examples

Embodiment Construction

[0019] Down-regulation of REDD1 expression can increase the sensitivity of bladder cancer to paclitaxel by inhibiting autophagy

[0020] Paraffin sections of 112 bladder cancer tissues and 32 normal bladder tissues were collected for immunohistochemical analysis. The results showed that compared with normal bladder tissue, REDD1 was significantly highly expressed in bladder cancer tissue ( figure 1A). Kaplan-Meier curves analysis found that bladder cancer patients with high expression of REDD1 had a poor prognosis ( figure 1 B).

[0021] Since REDD1 is highly expressed in BUC, and the high and low expression of REDD1 is closely related to the prognosis of patients, we further explored the effect of intervening REDD1 expression on the proliferation and apoptosis of bladder cancer cell lines. First, we analyzed the expression levels of REDD1 in bladder cancer cell lines BIU87, 5637, T24, EJ, and RT4, and found that the expression levels of REDD1 were higher in T24 and EJ with...